Hermetica Superfood Encyclopedia
The Short Answer
Cecropia spp. contains isoorientin, chlorogenic acid, procyanidins, and catechins that inhibit α-glucosidase (butanol extract IC₅₀ 14 μg/mL, exceeding acarbose), angiotensin-converting enzyme, and arginase at nanomolar-to-microgram concentrations. Methanolic leaf extracts reduced plasma glucose by 33.3–35.7% in mouse models, and stipule extracts achieved 91 ± 9% ACE inhibition, supporting preclinical rationales for antidiabetic and antihypertensive applications.
CategoryHerb
GroupAmazonian
Evidence LevelPreliminary
Primary KeywordCecropia benefits
Embaúva — botanical close-up
Health Benefits
**Blood Glucose Reduction**
Butanol fractions of Cecropia leaves inhibit intestinal α-glucosidase with an IC₅₀ of 14 μg/mL, outperforming the reference drug acarbose; methanolic extracts reduced plasma glucose 33.3–35.7% in healthy mice models.
**Antihypertensive Activity**: Methanolic stipule extracts from C
pachystachya achieved 91 ± 9% ACE inhibition; isoorientin and procyanidin C1 contributed 48 ± 1% and 45 ± 2% inhibition respectively at 0.33 mg/mL, mechanistically paralleling ACE-inhibitor drug classes.
**Anti-inflammatory Effects**
Chlorogenic acid, isoorientin, and isovitexin found predominantly in C. glaziovii modulate pro-inflammatory signaling pathways, consistent with traditional use of Cecropia leaf preparations for respiratory and systemic inflammation.
**Antioxidant Protection**: Ethanol extracts of C
mutisiana exhibited DPPH/ABTS radical scavenging with an IC₅₀ of 165.47 ± 3.0 ppm, attributed to the high total phenol content (up to 135.1 ± 6.4 mg gallic acid equivalents per gram in ethyl acetate fractions).
**Arginase Inhibition and Vascular Support**
Orientin demonstrates potent arginase inhibition (IC₅₀ 7 μM), an enzyme that competes with nitric oxide synthase for L-arginine; inhibiting arginase increases NO bioavailability, supporting vasodilation and endothelial function.
**Bronchodilatory and Respiratory Support**
Multiple Cecropia species have been used traditionally for asthma management, with flavonoids such as vitexin and isovitexin proposed to reduce airway inflammation and smooth muscle hyperreactivity, though direct bronchodilatory mechanisms remain under investigation.
**Immunomodulatory Safety Signal**
No cytotoxicity was detected in primary murine splenocyte cultures exposed to Cecropia extracts, suggesting a favorable immune-cell tolerability profile at tested concentrations and providing an early safety marker for further research.
Origin & History
Natural habitat
Cecropia is a genus of approximately 66 Neotropical tree species distributed across Central and South America, with pharmacologically studied species including C. pachystachya, C. glaziovii, and C. hololeuca concentrated in Brazilian biomes such as the Atlantic Forest, Cerrado, and Amazonia. These fast-growing pioneer trees thrive in disturbed forest margins, riverbanks, and secondary growth zones at low to mid elevations, tolerating high humidity and full sun. Traditional cultivation is largely absent; plants are harvested wild from natural populations, with leaves and stipules being the primary plant parts collected for medicinal use.
“Cecropia species, collectively called embaúva, ambay, or trumpet trees, have been used by indigenous and mestizo communities throughout the Amazon Basin, Brazilian Cerrado, and Andean foothills for centuries to treat respiratory ailments including asthma and bronchitis, as well as fever, hypertension, and diabetes. In Brazilian ethnomedicine, leaf and stipule preparations—often as aqueous decoctions or macerated in alcohol—are considered antidiabetic and diuretic remedies, with C. pachystachya and C. glaziovii representing the most commonly cited therapeutic species. Indigenous groups such as the Guarani and various Amazonian peoples have incorporated Cecropia bark and leaf poultices into wound-healing practices, attributing anti-inflammatory and cicatrizing properties to the plant. The genus name Cecropia references Cecrops, a mythical king of Athens, assigned by European naturalists during colonial botanical surveys, though the trees hold no classical European medicinal heritage and their pharmacological investigation began only in the late twentieth century.”Traditional Medicine
Scientific Research
The evidence base for Cecropia spp. consists entirely of in vitro assays and small-scale animal experiments; no peer-reviewed human clinical trials with defined sample sizes, randomization, or controlled endpoints have been published as of the available literature. Key in vitro findings—including α-glucosidase IC₅₀ values, ACE inhibition percentages, and DPPH radical scavenging capacities—have been replicated across at least three species (C. pachystachya, C. glaziovii, C. mutisiana), lending some consistency to preclinical data. Animal studies demonstrate plasma glucose reductions of 33–36% in mice using methanolic extracts, but sample sizes are not uniformly reported and studies lack standardized dosing protocols. Fewer than 10 of the 66 recognized species have undergone any pharmacological characterization, leaving a large evidence gap regarding species-specific potency, optimal extraction methods, and translatable human doses.
Preparation & Dosage
Traditional preparation
**Leaf Infusion (Traditional)**
2–5 g per 200 mL water, consumed 1–3 times daily in Brazilian folk medicine for diabetes and hypertension; no standardized preparation protocol exists
Dried leaves brewed as tea at approximately .
**Methanolic Leaf Extract (Research Grade)**
Used in preclinical studies at concentrations producing 33–36% glucose reduction in mice; human-equivalent doses have not been established or validated.
**Butanol Fraction (Research Grade)**
In vitro α-glucosidase inhibition observed at IC₅₀ 14 μg/mL; no clinical dosing translation available.
**Standardized Extract**
No commercial supplement standardization to isoorientin, chlorogenic acid, or procyanidin content has been formally established or regulatory-cleared.
**Timing Notes**
Traditional use typically involves consumption before or with meals to theoretically attenuate postprandial glucose; this practice is not supported by clinical evidence.
**Caution**
Absence of human pharmacokinetic data means no safe or effective dose range can be recommended for supplemental use at this time.
Nutritional Profile
Cecropia leaves are not consumed as a food and have no characterized macronutrient or micronutrient profile of nutritional significance. Phytochemically, total phenolic content in extracts ranges from moderate to high depending on species and solvent: up to 135.1 ± 6.4 mg gallic acid equivalents per gram in C. mutisiana ethyl acetate fractions. Key identified phytochemicals include C-glycosyl flavonoids (isoorientin, orientin, vitexin, isovitexin at varying percentages of extract dry weight), flavan-3-ols and procyanidins (catechin, epicatechin, procyanidin B2, procyanidin C1), phenolic acids (chlorogenic acid as the predominant compound across species, plus quinic and sinapic acid derivatives), and triterpenoids (pomolic acid, tormentic acid, β-sitosterol in C. pachystachya; saponin-O-hexosides in C. hispidissima). Bioavailability of C-glycosyl flavonoids such as isoorientin is generally lower than O-glycosyl flavonoids due to resistance to intestinal glycosidase hydrolysis, and their absorption is partly dependent on colonic microbial metabolism, a factor not yet studied in the context of Cecropia consumption.
How It Works
Mechanism of Action
Isoorientin and procyanidin C1 competitively inhibit angiotensin-converting enzyme by chelating its zinc active site and forming hydrogen bonds with key catalytic residues, reducing the conversion of angiotensin I to the vasoconstrictive angiotensin II. Catechin, epicatechin, and procyanidin B2 slow postprandial glucose absorption by inhibiting α-glucosidase enzymes in the intestinal brush border, delaying carbohydrate hydrolysis and glucose entry into systemic circulation. Orientin suppresses arginase I and II activity (IC₅₀ 7 μM), diverting L-arginine substrate toward endothelial nitric oxide synthase, thereby increasing nitric oxide production and promoting vasodilation. Chlorogenic acid and caffeoylquinic acid derivatives scavenge reactive oxygen species via electron donation, chelate redox-active metals, and may modulate NF-κB-mediated inflammatory gene transcription, accounting for combined antioxidant and anti-inflammatory activity observed across species.
Clinical Evidence
No randomized controlled trials or observational human studies have been identified for any Cecropia species. Available preclinical data from murine and in vitro models suggest antidiabetic, antihypertensive, and antioxidant potential, but these findings cannot be directly extrapolated to clinical efficacy or dosing in humans. Effect sizes observed in animal models—such as 33–36% plasma glucose reduction and >90% ACE inhibition in isolated stipule extracts—are promising but generated under non-standardized experimental conditions. Clinical confidence is very low; human pharmacokinetic, pharmacodynamic, and safety studies are entirely absent, making evidence-based clinical recommendations premature.
Safety & Interactions
Available safety data are limited to in vitro splenocyte culture studies showing no significant cytotoxicity, and no formal toxicological studies—acute, subacute, or chronic—have been published for any Cecropia species in peer-reviewed literature. The potent α-glucosidase and ACE inhibitory activity observed preclinically raises theoretical concern for additive hypoglycemic effects when combined with antidiabetic agents (metformin, sulfonylureas, GLP-1 agonists, insulin) and additive hypotensive effects with ACE inhibitors, ARBs, or calcium channel blockers, but no clinical interaction studies exist. Cecropia preparations are contraindicated in the absence of medical supervision for individuals on antidiabetic or antihypertensive medications, and safety during pregnancy and lactation has not been evaluated. Maximum safe doses for humans are entirely undefined; long-term safety is unestablished, and the significant phytochemical variability across 66 species means that safety conclusions from one species cannot be extrapolated to others.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Cecropia pachystachyaCecropia glazioviiCecropia hololeucaEmbaúvaAmbayTrumpet treeImbaúbaCecropia spp.
Frequently Asked Questions
What is Cecropia used for in traditional medicine?
Cecropia species, particularly C. pachystachya and C. glaziovii, have been used for centuries in Latin American folk medicine to treat diabetes, high blood pressure, asthma, and fever, primarily through leaf and stipule decoctions or macerated preparations. Indigenous and mestizo communities in Brazil, Argentina, and Amazonian countries commonly prepare aqueous or alcoholic leaf extracts consumed before meals for blood sugar and cardiovascular support, though these uses have not yet been validated in human clinical trials.
Does Cecropia lower blood sugar?
Preclinical research shows butanol fractions of Cecropia leaves inhibit intestinal α-glucosidase with an IC₅₀ of 14 μg/mL, a potency exceeding that of the pharmaceutical drug acarbose in the same assay, and methanolic extracts reduced plasma glucose by 33.3–35.7% in mouse experiments. However, no human clinical trials have been conducted, so the blood-sugar-lowering effect in people remains unconfirmed and no safe or effective human dose has been established.
Which Cecropia species is most studied for health benefits?
Cecropia pachystachya and Cecropia glaziovii are the most pharmacologically characterized species, with C. pachystachya featuring prominently in ACE inhibition, α-glucosidase inhibition, and antioxidant studies, while C. glaziovii is noted for its high chlorogenic acid content and anti-inflammatory flavonoid profile. C. mutisiana and C. hispidissima have also been studied to a limited extent, but fewer than 10 of the genus's approximately 66 species have undergone any pharmacological evaluation.
Is Cecropia safe to take as a supplement?
Safety data for Cecropia are extremely limited; the only published safety signal is the absence of cytotoxicity in murine splenocyte cultures at tested concentrations, with no human toxicity studies, no established maximum safe dose, and no pregnancy or lactation safety data. Individuals taking antidiabetic or antihypertensive medications should exercise particular caution, as Cecropia's potent α-glucosidase and ACE inhibitory activity could theoretically cause additive hypoglycemia or hypotension, though this interaction has not been clinically tested.
What are the main bioactive compounds in Cecropia?
The principal bioactive compounds in Cecropia are C-glycosyl flavonoids—especially isoorientin, orientin, vitexin, and isovitexin—along with flavan-3-ols (catechin, epicatechin) and oligomeric procyanidins (procyanidin B2 and C1), all of which contribute to antioxidant and enzyme-inhibiting activities. Chlorogenic acid is the predominant phenolic acid across species and is considered a key contributor to the genus's antidiabetic and anti-inflammatory pharmacology, with terpenoids such as pomolic acid and β-sitosterol present in smaller quantities in certain species like C. pachystachya.
How does Cecropia compare to pharmaceutical ACE inhibitors for blood pressure management?
Cecropia stipule extracts, particularly from C. pachystachya, demonstrate potent ACE inhibition (91 ± 9%) comparable to prescription medications, though clinical trials in humans are limited compared to established drugs like lisinopril. The bioactive compounds isoorientin and procyanidin C1 appear to be responsible for this activity, but Cecropia should be considered a complementary approach rather than a direct replacement for prescribed antihypertensives. More human clinical studies are needed to establish equivalent efficacy and optimal dosing protocols.
What is the most effective form of Cecropia for glucose control—leaf extract, stipule extract, or whole leaf?
Methanolic and butanol extracts of Cecropia leaves show superior efficacy in research models, with butanol fractions demonstrating exceptional α-glucosidase inhibition (IC₅₀ of 14 μg/mL, outperforming acarbose). Stipule extracts are particularly potent for ACE inhibition, suggesting different plant parts concentrate different bioactive compounds. Standardized extracts are likely more effective than whole leaf preparations, though human studies directly comparing forms are sparse.
Are there known drug interactions between Cecropia and diabetes or hypertension medications?
Because Cecropia exhibits both glucose-lowering and ACE-inhibitory properties, concurrent use with antidiabetic agents (metformin, sulfonylureas) or antihypertensive medications (ACE inhibitors, beta-blockers) may create additive effects and increase hypoglycemia or hypotension risk. No formal interaction studies have been published in humans, making clinical safety data limited. Individuals taking these medications should consult a healthcare provider before adding Cecropia supplementation to monitor for therapeutic interactions.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w cecropia-cecropia-spp curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
